Since PSMA uptake correlated with features of tumor aggressiveness like extracapsular infiltration or Gleason score, a miss of small or lower grade intraprostatic lesions may be acceptable for radiotherapy treatment planning [18], as PET volumes would currently only be used to deliver a boost dose within the prostate. The gene discussed is FOLH1; the disease is neoplasm.